Key result
Chronic treatment with the ETA receptor antagonist BQ-123 significantly decreased central mean arterial pressure and completely restored peripheral blood flow and endothelial function in rats with aortic stiffening.
Why the study?
Does ETA receptor antagonist BQ-123 improve peripheral vessel structure and function and lower blood pressure in rats with aortic stiffness-induced hypertension?
Does ETA receptor antagonist BQ-123 improve peripheral vessel structure and function and lower blood pressure in rats with aortic stiffness-induced hypertension?
Absolute Event Rate: 115% vs 131.3%
p-value: p=<0.05
ETA receptor blockade reverses hypertension and restores endothelial function in a rat model of aortic stiffening, highlighting a potential therapeutic target for aortic stiffness-induced hypertension.
ETA antagonism may reverse aortic stiffening effects in rats; leaves open human translation and trials.
Arterial stiffness may contribute to the pathogenesis of hypertension. The goal of this study is to elucidate the role of Endothelin-1 (ET-1) in aortic stiffening-induced hypertension through ET A receptor activation. An increase in aortic stiffness was created by use of a non-constrictive restraint, NCR on the abdominal aortic surface. A group of rats underwent aortic NCR or sham operation for 12 weeks and were then treated with ET A receptor antagonist BQ-123 for 3 weeks. We found that 12 weeks of aortic NCR significantly increased pulse and mean pressure and altered peripheral flow pattern, accompanied by an increased serum ET-1 level (p < 0.05). The increase in aortic stiffness (evidenced by an elevated pulse wave velocity) caused hypertrophic structural remodeling and decreased arterial compliance, along with an impaired endothelial function in peripheral small arteries. BQ-123 treatment only partially attenuated peripheral arterial hypertrophy and restored arterial compliance, but completely recovered endothelium function, and consequently restored local flow and lowered blood pressure. Our findings underscore the hemodynamic coupling between aortic stiffening and peripheral arterial vessels and flow dynamics through an ET A -dependent mechanism. ET A receptor blockade may have therapeutic potential for improving peripheral vessel structure and function in the treatment of aortic stiffness-induced hypertension.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2018) studied Aortic stiffening-induced hypertension (n=27). BQ-123 vs. Aortic NCR without treatment (Sham/Baseline) was evaluated on Central mean arterial pressure (mmHg) (p=<0.05). Chronic treatment with the ETA receptor antagonist BQ-123 significantly decreased central mean arterial pressure and completely restored peripheral blood flow and endothelial function in rats with aortic stiffening.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: